C19orf73: A Potential Drug Target and Biomarker for Chromosome 19 Open Reading Frame 73

Target Name: C19orf73

NCBI ID: G55150

C19orf73

Other Name(s): chromosome 19 open reading frame 73 | Chromosome 19 open reading frame 73 | CS073_HUMAN | Putative uncharacterized protein C19orf73 | putative uncharacterized protein C19orf73

C19orf73: A Potential Drug Target and Biomarker for Chromosome 19 Open Reading Frame 73

Chromosome 19 (19p) is one of the chromosomes responsible for generating the human genome. It is home to numerous gene mutations, including the gene C19orf73 (Chromosome 19 Open Reading Frame 73), which has been implicated in various diseases. The C19orf73 gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

C19orf73 gene and its function

C19orf73 is a 21-kDa protein that is located on chromosome 19, specifically on open reading frame (ORF) 73 (19pORF73). It is a non-coding RNA molecule that is expressed in various tissues and cells of the body. The primary function of C19orf73 is to interact with the protein p16INK4a, which is a negative regulator of the Ink4a gene.

C19orf73 has been shown to play a critical role in the development and progression of various diseases, including cancer. For instance, studies have shown that high expression of C19orf73 is associated with poor prognosis in cancer patients. Additionally, C19orf73 has been implicated in the regulation of cell cycle progression and has been shown to promote the growth and survival of cancer cells.

C19orf73 as a drug target

C19orf73 has been identified as a potential drug target due to its involvement in various diseases. One of the primary targets for C19orf73 is the protein p16INK4a, which is a negative regulator of the Ink4a gene. The Ink4a gene is a key regulator of the DNA damage response, and its dysfunction has been implicated in various diseases, including cancer.

Research has shown that the p16INK4a gene can be targeted by small molecules, including inhibitors of DNA-protein binding, which can lead to the inhibition of the Ink4a gene. This results in increased levels of p16INK4a, which can lead to the inhibition of the DNA damage response and the promotion of DNA damage-associated gene expression.

Another potential target for C19orf73 is the gene NOTCH1, which is responsible for the regulation of stem cell proliferation and differentiation. The NOTCH1 gene has been shown to be regulated by C19orf73, and the dysfunction of NOTCH1 has been implicated in various diseases, including cancer.

C19orf73 as a biomarker

C19orf73 has also been identified as a potential biomarker for various diseases. One of the primary biomarkers for cancer is the expression of the cancer-associated gene, PDGFRA. PDGFRA is a transmembrane protein that is involved in the regulation of cell proliferation and survival.

Studies have shown that the expression of PDGFRA is regulated by C19orf73, and the dysfunction of PDGFRA has been implicated in the development and progression of various diseases, including cancer. Additionally, C19orf73 has been shown to be involved in the regulation of the angiogenesis, which is the process by which new blood vessels are formed.

Conclusion

In conclusion, C19orf73 is a gene that has been implicated in various diseases, including cancer. Its function as a protein and its regulation by the protein p16INK4a and NOTCH1 make it a potential drug target and biomarker, respectively. Further research is needed to fully understand the role of C19orf73 in diseases and its potential as a drug and biomarker.

Protein Name: Chromosome 19 Open Reading Frame 73

The "C19orf73 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C19orf73 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets